Researchers have identified a first-trimester blood marker that could help predict preeclampsia and fetal growth restriction earlier in pregnancy, according to a new study published in Nature Medicine. The finding centres on Isthmin-2, or ISM2, a protein linked to extravillous trophoblast invasion, a key process in early placental development. The authors report that lower levels of ISM2 in early pregnancy may indicate a higher risk of developing these complications later on.
Why the finding matters for maternity care
Preeclampsia remains one of the most closely watched pregnancy complications because it can endanger both mother and baby, while fetal growth restriction can signal that a baby is not developing as expected in the womb. The study’s focus on the first trimester is notable because risk detection at that stage may allow clinicians to monitor pregnancies more closely and consider earlier intervention if the association is confirmed in wider clinical use.
The research used serum proteomics from pregnancy cohorts to examine how ISM2 behaves in early gestation. The authors say their work shows ISM2 is involved in extravillous trophoblast invasion, strengthening the biological case for why changes in the protein could be linked to later problems in placental function.
What the study adds to existing screening efforts
Current approaches to predicting preeclampsia often rely on a combination of clinical risk factors, blood pressure measurements and laboratory tests. A biomarker that reflects placental development in the first trimester could complement those methods and potentially improve early risk stratification. For UK maternity services, where prevention and timely surveillance are major priorities, that kind of advance could be clinically meaningful if future studies confirm the result. This is an inference based on the study’s early-pregnancy timing and its relevance to placental disease.
The paper does not by itself establish a new diagnostic test, and further validation would be needed before ISM2 could be used in routine care. Even so, the work points to a possible route for earlier identification of pregnancies at risk of serious complications.
Next steps for researchers
The most important question now is whether the marker can perform reliably across different populations and clinical settings. If so, it may support future screening strategies aimed at detecting preeclampsia and fetal growth restriction earlier than is currently possible. For now, the study offers a promising biological clue rather than a ready-made clinical tool.
As pregnancy research continues to shift toward earlier detection and prevention, ISM2 adds to growing interest in placental biomarkers that could reshape antenatal care. The broader challenge will be turning this kind of molecular insight into a test that is accurate, accessible and useful in everyday practice.
Photo source: AI-generated or edited image
